RGCRegencell Bioscience Holdings Limited
$7.30-53% 1Y
$7.30
$4.7552 weeks$52.88
RGC as reported
- Net income
- −$3.6M
Net income · −17% year on year · trailing twelve months to FY2025
- Free cash flow
- −$3.3M
Free cash flow · −18% year on year · trailing twelve months to FY2025
- EPS
- −$0.72
EPS · −17% year on year · trailing twelve months to FY2025
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$3.6M | −17% | FY2025 |
| EPS | −$0.72 | −17% | FY2025 |
| ROE | −74% | n/a | FY2025 |
| ROA | −62% | n/a | FY2025 |
| Free cash flow | −$3.3M | −18% | FY2025 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Regencell Bioscience Holdings Limited (RGC) · Net incomeNet incomeRegencell Bioscience Holdings Limited (RGC)
Drug Manufacturers, Specialty & Generic
Ranks #40 of 41 by RyuScore